Table 3 Relationship between TCP1 expression and clinicopathological features of EOC patients
From: TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells
| Characteristics | N | IOD/area | P |
|---|---|---|---|
| Age (years) | 0.271 | ||
| < 60 | 47 | 0.074 ± 0.043 | |
| ≥ 60 | 15 | 0.087 ± 0.037 | |
| Tumour size | 0.72 | ||
| < 5 cm | 14 | 0.074 ± 0.037 | |
| ≥ 5 cm | 48 | 0.078 ± 0.043 | |
| FIGO Stage (2009) | 0.001* | ||
| I + II | 30 | 0.060 ± 0.033 | |
| III + IV | 32 | 0.094 ± 0.043 | |
| Histological subtype | 0.052 | ||
| Serous | 38 | 0.086 ± 0.044 | |
| Mucinous | 17 | 0.065 ± 0.026 | |
| Clear cell | 4 | 0.014 ± 0.007 | |
| Endometrioid | 3 | 0.091 ± 0.069 | |
| Grade of differentiationa | 0.001* | ||
| Low | 27 | 0.050 ± 0.023 | |
| High | 35 | 0.091 ± 0.042 | |
| Lymph node metastasisb | 0.137 | ||
| Positive | 9 | 0.100 ± 0.048 | |
| Negative | 47 | 0.073 ± 0.040 | |
| The volume of ascites | 0.27 | ||
| Positive | 29 | 0.083 ± 0.039 | |
| Negative | 33 | 0.072 ± 0.044 |